预约演示
NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing
2023-11-15
临床2期
NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing
Proceeds will be used to complete three Phase 2 clinical studies of first-in-class ClC-1 molecule inhibitor NMD670 in myasthenia gravis, spinal muscular atrophy and Charcot-Marie-Tooth disease
In addition, NMD Pharma will continue to mature and expand its pipeline of novel ClClC-1nhibitors, and pursuNMD670sclomyasthenia gravisthspinal muscular atrophyesCharcot-Marie-Tooth disease
Aarhus, DenmaNMD Pharmaember 2023 – NMD Pharma A/S, a clinical-stage biotech dediClC-1 inhibitorsClC-1 to developing novel and improved treatments for patieneuromuscular diseasesuscular diseases, today announces that it has raised €75 million (~$80 million) in a Series B financing. The financing was led by current investor Jeito Capital and includes investments from other current NMD Pharma investors: Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, and the Roche Venture Fund.
NMD Pharma is developing first-in-clNMD Pharma A/Scule inhibitors of the skeletal muscle specific chloride ion channel (ClC-1) to enhance neuromuscular tranneuromuscular diseasesntial to restore muscle function in a range of rare neuromuscular diseases. Proceeds from the financing will be used to complete thJeito Capitaltudies with NMD670, the Company’s lead ClC-1 NMD Pharma The three sNovo HoldingsvaLundbeckfonden BioCapital oINKEF Capitalition in ARoche Venture Fundody positive myasthenia gravis, spinal muscular atrophy, and Charcot-Marie-Tooth disease, respectively.
NMD Pharmae, NMD Pharma will continue to expand its pipeline of ClC-1 inhibitor molecules and pursue undisclosed targets for the treatment of other neuromuscular diseases. The new funds will also be used to expand NMD Pharma’rare neuromuscular diseasesperations in Denmark and in the US.NMD670ClC-1 inhibitorClC-1ClC-1AChRMuSK antibody positive myasthenia gravisMuSKspinal muscular atrophyCharcot-Marie-Tooth disease
“This fundingNMD Pharma NMD Pharma evolve significantly and enabClC-1 inhibitorClC-1 to become a late-stage clinical company with a pipeline of novel therapeutics neuromuscular diseasesients with neuromuscular diseases” said ThomNMD Pharmadersen, Chief Executive Officer of NMD Pharma. “I would like to extend my thanks to my team for their work making NMD Pharma the company it is today and for the support and trust shown by our investors, and in particular to Jeito Capital, for leading this round.”
“NMD Pharma has progressNMD Pharmaeline of first-in-class CIC-1 inhibitors from the laboratory to the clinic in several severe neuromuscular diseases. This financing round will be pneuromuscular diseases as we aim to deliver the next phase of growth to becomeNMD Pharmaage clinical company, supported by this new capital and expert investNMD Pharmaow us well and are experienced in building shareholder value.” remarked Mike Heffernan, Chairman of Jeito CapitalNMD Pharma.
SNMD Pharmaiguian, Managing Partner at lead investor JeitoCIC-1 inhibitors “Since we originally looked at NMD Pharma we have beneuromuscular diseasesCompany’s unique expertise in a very specialized area. The Company has matured and grown significantly since our initial investment last year and the recent positive clinical data has provided valuable validation. As such, we are very pleased to lead this new round and look forward to supporting Thomas Holm PedNMD Pharma CEO, and his talented team as they progress the NMD Pharma story to the next chapter with a joint ambition: provide patients with life transforming benefits.”
Contacts
NMD Pharma A/S
NMD Pharma A/SVP, Corporate and Commercial Strategy
E-mail: contact@nmdpharma.com
ICR Consilium
Mary-Jane Elliott / Ashley Tapp / Lindsey Neville
E-mail: NMDPharma@consilium-comms.com
Tel: +44 (0)20 3709 5700
About NMD Pharma
NMD PhNMD Pharmas a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively targeting the skeletal muscle chloride ion channel (ClC-1) for the treatment of severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received initial seed financing in 2016 and has since raised ~€155 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital. Find out more about us online at http://www.nmdpharma.com/.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。